

Fig. 1



Fig. 2



Fig. 3





Fig 4A



Fig 4B



Fig 5


TO
Syringe
pump
Detection
Region
Grooved
Cover
Test Sample
PTFE
Tube
measurement
probe
HP 8510
Network
Analyzer
Port 1
Computer

Fig 6.



fig 7


812
814
810
818
816
834

Fig 8A


810
826
I/O CONTROLLER
SYSTEM MEMORY
CENTRAL PROCESSOR
SPEAKER
824
828
830
840
840
DISPLAY ADAPTER
834
836
838
MONITOR
REMOVABLE DISK
KEYBD
FIXED DISK
NETWORK INTERFACE
814
832

FIG. 8B

MCS: RF and Microwave



- **Detects protein "soft vibrations"**
  - *Protein Motions 10 psec – 100 nsec*
- **Complexation of Solvent**
  - Water, ions, cofactors, small molecules, other proteins



Signature BioScience, Inc

Integration of the Biology

- Biological systems as dielectric circuit element
- Integration into circuit configurations



Solution-Phase



Solid-Phase

Permittivity vs. Structure:
Fibrinogen Digest





Signature BioScience, Inc

Tyrosine kinase assay

.132 units/ul c-src, 200 uM (.3 mg/ml) substrate (521) and 150 uM ATP



Signature BioScience, Inc

MCS broadband signatures

Differ between proteins



Signature BioScience, Inc

Value Proposition

- Permittivity→Function

- No Engineering→Direct and Rapid Access

Signature BioScience, Inc

MCS in Drug Discovery:

A Parallel Approach



Signature BioScience, Inc

MCS: solving discovery problems

- "Target-fishing"
  - we can detect proteins in solution
  - we can classify unknown protein targets
  - we can de-orphan unknown protein targets
- Quantifying binding
- Qualifying leads using protein/ligand classification with MCS
- SAR using MCS
- Cellular assays with MCS

Signature BioScience, Inc

MCS in Drug Discovery



- **Quantified binding measurements**
- **Label-free assays**
- **Rapid assay prototyping and development**
- **Physiologically relevant conditions**
- **Medium throughput**
- **Molecular system**

Signature BioScience, Inc

Similar proteins have similar signatures

Change in permittivity at 1.3 GHz





Signature BioScience, Inc

MCS cellular response to ionomycin



Signature BioScience, Inc

Thapsigargin



~~Roger Plot~~



Signature BioScience, Inc

Multiple Discrete Frequency Analysis



ature
BioScience, Inc

Tertiary structural homology prediction



Clustering for protein function



(hypothetical)

Signature BioScience, Inc

Or, de-orphaning using annotated compound libraries…



Signature BioScience, Inc

...Enabling clustering for compound effect

(hypothetical)



Signature BioScience, Inc

Non-competitive binding assays

- Methods to detect weak binders are slow
  - Competitive assays usually won't work
- "Orphan-like" targets may have no affinity ligand
- Allosteric binders difficult to find
- Label artifacts
- Bioconjugation

IL-2/IL-2R Inhibitors

IL-2 is the principle cytokine involved in cell-mediated immunity.

Antibodies against IL-2Rα approved for graft rejection.

- Well-characterized small-molecule inhibitors of IL-2 have been discovered



IC_{50} = 3 μM

sunesis

Roche Research Center (Nutley)
J.W. Tilley, et al. JACS (1997) 119, 7589-7590.

Signature BioScience, Inc

MCS analysis of binding to IL-2, IL-4



Signature BioScience, Inc

MCS binding results same as others

Method	IC_{50}/K_d
SPA	3 μM
MCS	***4 μM***
AUC	5 μM
SPR	20 μM
ITC	4 μM



SPA – scintillation proximity assay
MCS – multipole coupling spectroscopy
AUC – analytical ultracentrifugation
SPR – surface plasmon resonance
ITC – isothermal calorimetry

Signature BioScience, Inc

MCS in Drug Discovery

Drug Discovery Process



Signature BioScience, Inc

Ligand function classification

- "Bin" hits
  - agonists would cause similar responses to each other
    - distinct responses from antagonists
- Nuclear Receptor-based
  - "binning" of hits
  - quantify relationships to known compounds
    - e.g. Ligand-1 like or Ligand-2 like

Lack of a functional readout is a problem

- No ready, quick method for categorizing the effect a "hit" chemical has on a given target, when certain profiles are desired (ie, a functional, but not chemical, copy)
- Clear desire for a fast means of "target-fishing" using annotated compound libraries and other techniques

MCS of NR – L1 interaction at 1.3 GHz



Signature BioScience, Inc

NR/ligand interaction comparison



Signature BioScience, Inc

...Enabling clustering for ligand function (hypothetical)



Signature BioScience, Inc

Structure/activity using MCS ?

- The opportunity:
- Perform X-ray crystallography or NMR routinely
- Earlier in the discovery process
- The problem:
- Cost, reagents required, technology repertoire limitations, and time-consuming nature of the processes involved, are prohibitive

Protein Function: Estrogen receptor-ligand interaction

- X-ray analysis has shown that DES (agonist) and Tamoxifen (antagonist) cause subtly different conformation changes to ER on binding interaction



Signature BioScience, Inc

MCS signatures correlate interaction data

SAR Data from ER Model System

SAR with MCS – x-ray in advance

- Obtaining predicted structural readouts, enabled by "wet-lab" MCS data, and augmented by unique software…
  - Jump starts SAR, typically undertaken later

...Enabling clustering for ligand function (hypothetical)



Signature BioScience, Inc

MCS in Drug Discovery



- SAR by MCS
- Determine binding IC_{50}s
- Determine EC_{50}s on cellular assays
- Eliminate compounds for ADMET problems
- Determine specificity
- Cellular systems, some molecular

Signature BioScience, Inc

MCS: solving discovery problems

- "Target-fishing"
  - we can detect proteins in solution
  - we can classify unknown protein targets
  - we can de-orphan unknown protein targets
- Quantifying binding
- Qualifying leads using protein/ligand classification with MCS
- SAR using MCS
- Cellular assays with MCS

Signature BioScience, Inc

Cellular MCS: Overview

- Protein structure→cell organization
- Many physiologic processes can be measured
  - GPCR-mediated pathway induction
  - Ion channel modulation
  - Morphologic changes
  - Apoptotic events

Cellular MCS

- Protein Structure→Cellular Organisation
- MCS Measures Physiologic Changes in Cells
  - Ion Flux
  - Cytosolic cAMP/Ca2+
  - Morphologic Changes
  - Membrane changes

Signature BioScience, Inc

Specificity in MCS Cellular Analyses

- Spectral Response
- Kinetics
- "Orthogonal" properties
  - Protein expression levels
  - Focused libraries
  - Diverse cell populations

Signature BioScience, Inc

MCS hits major screening bottlenecks…

- Target ID, validation, *access* ✓
- Rapid Assay Development ✓
- Secondary Screening and Lead Optimization ✓
- Data Management and Analysis ✓

Signature BioScience, Inc

...and MCS meets defined "drivers" for new detection technologies

- Simple one step homogeneous assay ✓
- Avoid radioactivity, safety, disposal costs ✓
- Sensitivity to replace radioactivity ✓
- Reagent, target and compound sparing ✓
- Speed / throughput ✓
- Higher quality information ✓



Signature BioScience, Inc

A GPCR-mediated pathway:

Activation of muscarinic m_1 receptor



CHO_{m1} Cell

Signature BioScience, Inc

Ca Flux 2º Assay on LJL Analyst



Signature BioScience, Inc

CPW

- 50MHz – 1GHz
- 101 points, -10 dBm
- IF Bandwidth – 10Hz
- SP11 & SP21
- Au & Pt chips
- $5x10^4$ cells/well plated the day before
- Vivian's New Sucrose Buffer

M1 Cells on .505 Pt CPW



Signature BioScience, Inc

MCS cellular response

- CHO cells – wild type and transfected with well-known GPCR (Gq-coupled)
- Agonist stimulation is seen in transfected cells, not in WT cells
- 2ndary assay: Calcium flux measured in LJL Analyst



Signature BioScience, Inc

MCS cellular response

- Same cell lines as previous slide
- Agonist stimulation is blocked by pre-treatment with 1 µM antagonist



Signature BioScience, Inc

Time course of response to agonist



Signature BioScience, Inc

Dose-Response Curves:

CHO-K1 vs. CHO-M1 : carbachol





Signature BioScience, Inc

PZP Dose curves … MCS & Ca^{+2} Flux

CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine



Signature BioScience, Inc

300 nM Carb + PZP

CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine



Signature BioScience, Inc

M1 – 300 nM Carb vs PZP Doses

Conclusions:

- PZP always blocks activation by 300 nM Carbachol
- Dose of PZP required to block Carb response varies everyday (look at 3 nM, 10 nM)
- Range of positive response can vary a lot



~~Roger Plot~~...

Signature BioScience, Inc









~~Simon plot~~..

Signature BioScience, Inc

Dose-Response vs. Inhibitor

(Telenzepine)



Signature BioScience, Inc